Biotech Growth Trust has emerged as one of the strongest investment trusts during the period of market disruption linked to the Iran conflict, putting the trust firmly back on the radar as biotechnology attracts renewed attention.
Between 2 March and 31 August 2026, Biotech Growth Trust delivered a 38.5% share price total return. That placed it second among the 20 best-performing investment trusts over the period, behind only Molten Ventures at 53.0% and ahead of Allianz Technology Trust at 33.3%.
The Iran conflict affected energy markets, shipping routes and economic expectations, increasing uncertainty across global equities. Against that background, the strongest investment trust sectors were not limited to traditional defensive areas. Technology, growth capital, renewable energy infrastructure and healthcare and biotechnology all featured prominently.
Healthcare and biotechnology trusts as a group recorded a 15.8% share price total return over the same period. Biotech Growth Trust therefore performed substantially ahead of its broader sector. It also led the other biotechnology-focused trusts appearing among the top 20. International Biotechnology recorded a 24.9% share price total return, while RTW Biotech Opportunities returned 20.6%. Biotech Growth Trust’s 38.5% figure placed it clearly ahead of both.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
